Das ist der Job
HMNC Brain Health (HMNC) is a clinical-stage neuroscience company pioneering new therapies for mental health disorders.
Darum lohnt es sich
Used with a genetic test to identify patients most likely to benefit, Nelivabon offers a precision neuroscience approach to treatment. Its pipeline includes Nelivabon (BH-200), a vasopressin V1b receptor antagonist being developed as a biomarker-guided precision therapy for biologically defined depressive disorders.
HMNC is also developing Ketabon (KET01), an oral prolonged-release ketamine formulation for treatment-resistant depression, designed as a differentiated and scalable option for outpatient and at-home use.
By advancing targeted and accessible treatment options, HMNC aims to address significant unmet needs of millions of patients who are not helped sufficiently by existing mental health therapies. The Company is headquartered in Munich, Germany.
